Worried About Johnson & Johnson’s Valuation? Consider This Crazy Undervalued, 4.2% Yielding Pharmaceutical Stock Instead

Posted On March 30, 2017 5:55 pm

Johnson & Johnson is one of the best dividend growth stocks you can own. However, at today’s valuation investors might want to consider waiting for a pullback. In the meantime here’s a high-yielding alternative pharma stock, one that is 40% undervalued, and could be one of the best performer of the coming years.

Continue Reading Here

About author

Dividend Sensei

I'm an Army veteran and former energy dividend writer for The Motley Fool. I'm a proud co-founder of Wide Moat Research, Dividend Kings, and the Intelligent Dividend Investor. My work can be found on Seeking Alpha, Dividend Kings, iREIT, and the Intelligent Dividend Investor. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams and enrich their lives. With 24 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams and achieving long-term financial goals.

Related Articles

Leave a reply

Your email address will not be published. Required fields are marked *